Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Clinical Translation of Stem Cells 2014

Gregorio Chazenbalk's Biography

Gregorio Chazenbalk, Research Associate, Dept of Obstetrics and Gynecology, University of California-Los Angeles

As a basic scientist with more than 30 years of experience in molecular and cellular biology, Dr Chazenbalk has demonstrated substantial leadership experience in directing successful and productive research. His efforts has produced a body of work in the fields of molecular endocrinology, immunology, and cell biology resulting in more than 100 publications in prestigious journals such as Science, Proceedings of the National Academy of Sciences of the United States of America, Journal of Clinical Investigation, Journal of Biological Chemistry, Journal Clinical Endocrinology and Metabolism, and others. Early in his career, Dr Chazenbalk was awarded multiple scholarships from the Argentine Foundation of Endocrinology, the National Research Council of Argentina and the Argentine Endocrinology Foundation. After working for more than 20 years in thyroid research at the VA Hospital of San Francisco, the University of California, San Francisco (UCSF) and in the Thyroid Autoimmunity Disease Unit at Cedars Sinai Medical Center, Los Angeles, Dr Chazenbalk has been recognized internationally as an expert in thyroid regulation and autoimmunity. During that period, Dr Chazenbalk cloned the entire repertoire of human thyroid peroxidase autoantibodies which play a critical role in Hashimoto’s thyroiditis and conducted critical studies on the structure-function of the human thyrotropin receptor (TSHR), primary antigen of Graves’ disease. In addition, Dr Chazenbalk has pioneered discoveries on the cleavage site of the human thyrotropin receptor which has wide-ranging implications for the understanding of the pathophysiology of Graves’ Disease at both the molecular and cellular levels. His work in this field led him to successfully engineer the human thyrotropin receptor A subunit. The availability of this protein ignited further studies illuminating its crucial role in the initiation and/or amplification of the autoimmune response in Graves disease. Dr Chazenbalk was honored in 2001 to receive the prestigious award “Best Thyroid Scientist” from the Latin American Thyroid Association for my work in this field. In 2006, Dr Chazenbalk joined the Department of Obstetrics and Gynecology at Cedars-Sinai Medical Center as a scientist and as a member of the faculty of the Departments of Medicine and Obstetrics and Gynecology at UCLA. Since that time, Dr Chazenbalk has examined the role of inflammation in insulin resistance in adipose tissue of patients with Polycystic Ovary Syndrome (PCOS). Dr Chazenbalk was the first scientist to demonstrate that the accumulation of preadipocytes can be accelerated in vitro via cross-talk between adipocytes and resident macrophages and adipose stem cells, which can generate new adipocytes. This phenomenon may lead to the development of novel methods of tissue regeneration and reconstructive medicine, as well as in 2013, Dr Chazenbalk discovered a novel population of stem cells with pluripotent characteristics isolated from human adipose tissue. Despite their pluripotency, these stem cells do not produce teratomas in vivo, offering new avenues to treat many disorders (stroke, heart attack, diabetes, neurodegenerative and immune disorders, etc). This discovery has made a significant impact in the fields of regenerative medicine and cell therapy and has been recognized in the national and international media. It has also led to a patent application entitled “Pluripotent Human Adipose Adult Stem Cells: Isolation, Characterization and Clinical Implications.” Dr Chazenbalk received in 2014 an award from the Japanese Society of Science for his work in this field and to be invited to serve as the Editor of a scientific book entitled, “Muse Cells: A New Era of Pluripotent Stem Cells”, which is scheduled for publication by Springer in September 2015.

Gregorio Chazenbalk Image

Muse Cells Derived from Adipose Tissue: A New Perspective on the Clinical Potential of Adult Pluripotent Stem Cells

Tuesday, 22 April 2014 at 17:00

Add to Calendar ▼2014-04-22 17:00:002014-04-22 18:00:00Europe/LondonMuse Cells Derived from Adipose Tissue: A New Perspective on the Clinical Potential of Adult Pluripotent Stem CellsClinical Translation of Stem Cells 2014 in Palm Springs, California, USAPalm Springs, California,

The gold standard human pluripotent stem cells, embryonic and induced pluripotent stem cells have self-renewal uncontrolled capacity which often materializes in teratoma formation. A novel population of human pluripotent stem cells derived from adipose tissue (AT), termed Multilineage Differentiating Stress Enduring (Muse) (Muse-AT cells) was recently introduced to the scientific community, offering a resolution to the teratogenesis issue that plague ES and iPS cells. Muse-AT have self-renew capacity in a controlled manner without forming teratomas when injected into immune-deficient mice. Muse-AT cells are obtained from lipoaspirate material without the need of genetic manipulation nor the use of cell sorting techniques. Muse-AT cells express classic pluripotency markers and differentiate into cells from the three embryonic germ layers both spontaneously and under media-specific induction.  Muse-AT cells exist in a quiescent state under normal physiological circumstances within the cellular niche. Furthermore, Muse-AT cells may function according to a highly conserved cellular mechanism related to cell survival in response to severe cellular stress, as well as the functional regeneration of damaged tissues and amputated limbs in primitive species. Because lipoaspiration is a safe and non-invasive procedure and Muse-AT cell isolation requires a simple yet highly efficient purification technique, Muse-AT cells could provide an ideal source of pluripotent-like stem cells with the potential to have a critical impact on regenerative medicine and cell-based therapy.

Add to Calendar ▼2014-04-21 00:00:002014-04-22 00:00:00Europe/LondonClinical Translation of Stem Cells 2014Clinical Translation of Stem Cells 2014 in Palm Springs, California, USAPalm Springs, California,